Fig. 3. TSA treatment reduced the frequencies of DCs in spleen during the ACD development, but did not affect the frequencies of migrated epidermal LC and langerin⁺ dermal DCs in dLNs.

(A) Representative FACS dot plots for CD11C⁺ cells in spleen and dLNs from ACD mice treated with TSA or DMSO as controls. (B) Summary of data for the frequencies of CD11C⁺ cells in spleen and dLNs in the two groups, *p<0.05. (C) Representative FACS dot plots for subpopulations of CD11C⁺DCs based on CD4 and CD8 expression. (D) Summary of data for the frequencies of CD8⁺CD4⁻CD11C⁺, CD8⁻CD4⁻CD11C⁺, and CD8⁻CD4⁺CD11C⁺ cells in spleen and dLNs. (E) Representative FACS dot plots for skin immigrant DCs in dLNs. The migrated epidermal LCs (CD11C⁺langerin⁺CD103⁻CD8⁻DCs), migrated dermal langerin⁺ DCs (CD11C⁺langerin⁺CD103⁺CD8⁻), and LN-resident langerin⁺ DCs (CD11C⁺langerin⁺CD8⁺) were analyzed on gated Langerin⁺CD11c⁺ DCs in dLN. (F) Summary of data for the frequencies of CD11C⁺langerin⁺CD8⁻CD103⁻, CD11C⁺ langerin⁺ CD8⁻ CD103⁺, and CD11C⁺ langerin⁺ CD8⁺ cells in dLNs. Representative results of three independent experiments are shown. Data are presented as mean ± SD (N=5/group).